ArticleProceedings of the National Academy of Sciences of the United States of America2020
Activating
Open access · greenAbstract read
In one paragraph
Article in Proceedings of the National Academy of Sciences of the United States of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
5.9field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 77 citations in OpenAlex.
- Ferroptosis in multiple myeloma: molecular mechanisms and therapeutic opportunities.Frontiers in oncology · 2026Review
- Proteomic Perspectives on KRAS-Driven Cancers and Emerging Therapeutic Approaches.Current oncology (Toronto, Ont.) · 2025Review
- Targeting proteostasis for cancer therapy: current advances, challenges, and future perspectives.Molecular cancer · 2025Review
- Liquid Biopsy as a Means of Assessing Prognosis and Identifying Novel Risk Factors in Multiple Myeloma.International journal of molecular sciences · 2025Article
- Pan-Cancer Analysis of Oncogenic MET Fusions Reveals Distinct Pathogenomic Subsets with Differential Sensitivity to MET-Targeted Therapy.Cancer discovery · 2025Article
- Article
- Targeting ubiquitin-independent proteasome with small molecule increases susceptibility in pan-KRAS-mutant cancer models.The Journal of clinical investigation · 2025Article
- Rat Sarcoma Virus Family Genes in Acute Myeloid Leukemia: Pathogenetic and Clinical Implications.Biomedicines · 2025Review
- Network analysis of master regulators associated with invasive phenotypes in multiple myeloma.Frontiers in cell and developmental biology · 2025Article
- Identification and validation of a histone modification-related gene signature to predict the prognosis of multiple myeloma.Frontiers in genetics · 2025Article
- Identification of USP2 as a novel target to induce degradation of KRAS in myeloma cells.Acta pharmaceutica Sinica. B · 2024Article
- MiR-34c-5p Inhibition Affects Bax/Bcl2 Expression and Reverses Bortezomib Resistance in Multiple Myeloma Cells.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2024Article
- Enhancing mutation detection in multiple myeloma with an error-corrected ultra-sensitive NGS assay without plasma cell enrichment.Cancer cell international · 2024Article
- Characterization of the small Arabidopsis thaliana GTPase and ADP-ribosylation factor-like 2 protein TITAN 5.Journal of cell science · 2024Article
- Leukemic Stem Cells and Hematological Malignancies.International journal of molecular sciences · 2024Review
- Characterization of the smallbioRxiv : the preprint server for biology · 2024Article
- Targeting RAF dimers in RAS mutant tumors: From biology to clinic.Acta pharmaceutica Sinica. B · 2024Review
- Acute accumulation of PIM2 and NRF2 and recovery of β5 subunit activity mitigate multiple myeloma cell susceptibility to proteasome inhibitors.International journal of hematology · 2024Article
- Mechanisms of the role of proto-oncogene activation in promoting malignant transformation of mature B cells.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2024Article
- DNA Sequencing of CD138 Cell Population Reveals TP53 and RAS-MAPK Mutations in Multiple Myeloma at Diagnosis.Cancers · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Fazal ShiraziDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
Richard J JonesDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
Ram K SinghDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.ORCID 0000-0002-7654-1212
Jianxuan ZouDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
Isere KuiatseDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
Zuzana BerkovaDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.ORCID 0000-0001-8196-6517
Hua WangDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
Hans C LeeDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
Samuel HongDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
Larry DickMillennium: The Takeda Oncology Company, Cambridge, MA 02139.
Nibedita ChattopadhyayMillennium: The Takeda Oncology Company, Cambridge, MA 02139.
Robert Z OrlowskiDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030; rorlowski@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USTakeda (United States) · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MSWOG - Foreign Accrual under UMiU10CA032102 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BLANKE, CHARLES D. · 1985 to 2013
$141.3MP4 -TARGETING MULTIPLE MYELOMA BY COMBINING CDK INHIBITORS AND BCL-2 ANTAGONISTSP50CA142509 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KWAK, LARRY W · 2010 to 2014
$11.1MProteasome Assembly Chaperones in Sensitivity and Resistance to Proteasome InhibitorsR01CA194264 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ORLOWSKI, ROBERT ZYGMUNT · 2016 to 2020
$1.8MRole of TJP1 in Sensitivity and Resistance to Proteasome Inhibitors in MyelomaR01CA184464 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ORLOWSKI, ROBERT ZYGMUNT · 2015 to 2019
$1.8MNCI NIH HHS P30 CA016672NCI NIH HHS P50 CA142509NCI NIH HHS R01 CA184464NCI NIH HHS R01 CA194264NCI NIH HHS U10 CA032102
Abstract
PubMed holds no abstract for this paper.
Indexed as
Endoplasmic Reticulum StressApoptosisBortezomibGTP PhosphohydrolasesHumansMembrane ProteinsMultiple MyelomaMutationProteasome Endopeptidase ComplexProtein Kinase InhibitorsProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)BortezomibGTP PhosphohydrolasesKRAS protein, humanMembrane ProteinsNRAS protein, humanProteasome Endopeptidase ComplexProtein Kinase InhibitorsProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)BRAFKRASNRAFproteasome capacityproteasome inhibitor sensitivity
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.